Skip to main content
Boryung Corporation logo

Boryung Corporation — Investor Relations & Filings

Ticker · 003850 ISIN · KR7003850005 KO Manufacturing
Open in API
Filings indexed 354 across all filing types
Latest filing 2020-03-12 Audit Report / Informat…
Country KR South Korea
Listing KO 003850

About Boryung Corporation

https://pharm.boryung.co.kr/eng/index.do

Boryung Corporation is a fully integrated healthcare company founded in 1957. Its core business encompasses the research, development, manufacturing, and global commercialization of pharmaceutical products, with a significant presence in the cardiovascular therapeutic area. The company is distinguished by its pioneering 'Care in Space' (CIS) initiative, which focuses on developing healthcare solutions for humans in extreme environments and leveraging space for new research opportunities. In addition to its pharmaceutical operations, Boryung functions as a healthcare investment company, fostering innovation across the health sector. The company's diverse portfolio includes prescription drugs, over-the-counter products, and a pipeline aimed at addressing future medical needs.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from Boryung Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, net income), and details regarding the auditor (Samil PwC). While it contains financial data, it is a formal notification of the submission of the audit report to the regulatory body, which is a standard disclosure requirement in the Korean market. Given the document length and its nature as a formal notification of the audit report's availability and key summary figures, it fits the 'Audit Report / Information' (AR) category. FY 2019
2020-03-12 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Boryung Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and dividend proposals. It also includes detailed management information, board activity reports, and financial statements (balance sheet, income statement, etc.) as required by Korean law for shareholder review prior to the meeting. This is a classic Proxy Solicitation document used to inform shareholders and request their votes for the AGM.
2020-03-04 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted by Boryung Pharmaceutical to explain why their Annual General Meeting (AGM) is being held on a 'concentrated date' (a date when many other companies are also holding their AGMs). It provides the date, the reason for the scheduling conflict, and confirms the meeting notice date. Since it is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2020-03-04 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Boryung Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the date of the board resolution. This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2020-02-27 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a resolution to convene a General Meeting of Shareholders (주주총회소집결의) for Boryung Pharmaceutical. It outlines the date, location, and agenda items (financial statements, director appointments, etc.) for the upcoming meeting. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2020-02-27 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from Boryung Pharmaceutical regarding a significant change in sales or profit structure (30% or more). It provides preliminary financial highlights (revenue, operating profit, net income) for the fiscal year compared to the previous year. It explicitly states that these are preliminary figures subject to change by external auditors. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting material financial changes, which falls under the 'Earnings Release' category as it provides the initial announcement of financial results.
2020-01-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.